Compare EXFY & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXFY | EQ |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 129.0M |
| IPO Year | 2021 | 2018 |
| Metric | EXFY | EQ |
|---|---|---|
| Price | $1.05 | $2.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 590.0K | 370.4K |
| Earning Date | 05-07-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,101,000.00 | $41,095,000.00 |
| Revenue This Year | $0.42 | N/A |
| Revenue Next Year | $0.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.06 | N/A |
| 52 Week Low | $0.69 | $0.29 |
| 52 Week High | $3.06 | $2.70 |
| Indicator | EXFY | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 66.71 | 52.83 |
| Support Level | $0.77 | $1.60 |
| Resistance Level | $1.54 | $2.13 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 100.00 | 49.06 |
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.